类风湿关节炎中停用或减量生物改善病情抗风湿药时失去缓解、低疾病活动度或影像学进展的风险:文献系统分析与荟萃分析
该系统分析与荟萃分析评估类风湿关节炎(RA)已达缓解或低疾病活动度(LDA)患者停用或减量生物改善病情抗风湿药(bDMARDs)对比继续原方案的风险,检索至2017年5月。停用bDMARDs增加失去缓解、失去LDA及影像学进展风险;减量增加失去缓解风险,但不增加失去LDA或影像学进展风险。
要点
- 停用bDMARDs增加失去缓解(RR 1.97)、失去LDA(RR 2.24)及影像学进展(RR 1.09)风险。
- 减量bDMARDs增加失去缓解风险(RR 1.23),但不增加失去LDA或影像学进展风险。
- 停用与减量bDMARDs对RA缓解期患者疾病控制的影响不同。
核心结论
- 停用bDMARDs导致失去缓解或LDA及影像学进展风险增加;减量bDMARDs虽增加失去缓解风险,但不增加LDA复发或影像学进展风险。
研究设计与样本
- 系统文献分析检索至2017年5月的PubMed、Embase、Cochrane及国际会议数据库,纳入比较bDMARDs停用/减量与继续治疗在RA缓解或LDA患者中的对照试验。
- 停用对比继续的荟萃分析纳入9项试验;减量对比继续的荟萃分析纳入11项试验。
主要发现
- 停用bDMARDs对比继续治疗:失去缓解风险RR(95%CI)=1.97(1.43至2.73),P<0.0001;失去LDA风险RR(95%CI)=2.24(1.52至3.30),P<0.0001;影像学进展风险RR(95%CI)=1.09(1.02至1.17),P=0.01。
- 减量bDMARDs对比继续治疗:失去缓解风险RR(95%CI)=1.23(1.06至1.42),P=0.006;失去LDA风险RR(95%CI)=1.02(0.85至1.23),P=0.81;影像学进展风险RR(95%CI)=1.09(0.94至1.26),P=0.26。
关键数值与推荐
- 停用bDMARDs对比继续治疗:失去缓解RR(95%CI)=1.97(1.43至2.73),P<0.0001;失去LDA RR(95%CI)=2.24(1.52至3.30),P<0.0001;影像学进展RR(95%CI)=1.09(1.02至1.17),P=0.01。
- 减量bDMARDs对比继续治疗:失去缓解RR(95%CI)=1.23(1.06至1.42),P=0.006;失去LDA RR(95%CI)=1.02(0.85至1.23),P=0.81;影像学进展RR(95%CI)=1.09(0.94至1.26),P=0.26。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the risk of losing remission, low disease activity (LDA) or radiographic progression in the case of (1) discontinuing or (2) tapering doses of biological disease-modifying antirheumatic drugs (bDMARDs) compared with continuation of the initial treatment regimen in rheumatoid arthritis (RA) patients with remission or LDA. MATERIALS AND METHODS: A systematic literature analysis was carried out through May 2017 on the PubMed, Embase, Cochrane and international congress databases, selecting controlled trials comparing bDMARDs discontinuation/tapering versus continuation in RA patients with remission or LDA. The meta-analysis assessed the risk ratio (RR) and 95% CI of losing remission or LDA and the risk of radiographic progression after (1) discontinuing and (2) tapering doses of bDMARDs versus continuing the initial treatment. RESULTS: The meta-analysis comparing bDMARDs discontinuation versus continuation performed on nine trials showed an increased risk of losing remission (RR (95% CI)=1.97(1.43 to 2.73), P<0.0001) or LDA (RR (95% CI)=2.24(1.52 to 3.30), P<0.0001) and an increased risk of radiographic progression (RR (95% CI)=1.09(1.02 to 1.17), P=0.01) in case of bDMARD discontinuation. The meta-analysis comparing bDMARDs tapering versus continuation performed on 11 trials showed an increased risk of losing remission (RR (95% CI)=1.23(1.06 to 1.42), P=0.006) but no increased risk of losing LDA (RR (95% CI)=1.02 (0.85 to 1.23), P=0.81) nor any increased risk of radiographic progression (RR (95% CI)=1.09(0.94 to 1.26), P=0.26) in case of bDMARD tapering. CONCLUSION: Discontinuation of bDMARDs leads to an increased risk of losing remission or LDA and radiographic progression, while tapering doses of bDMARDs does not increase the risk of relapse (LDA) or radiographic progression, even though there is an increased risk of losing remission.
引用
- Henaux S, Ruyssen-Witrand A, Cantagrel A, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis. 2017. PMID: 29187350. doi:10.1136/annrheumdis-2017-212423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。